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Abstract
It is now understood that persistent activation of the androgen receptor (AR) signaling pathway often underlies the
development of castration-resistant prostate cancer (CRPC). This realization led to renewed interest in targeting the
AR and ultimately to the development of the potent next-generation AR-directed agents abiraterone and enzalutamide.
While these drugs prolong survival in men with CRPC, they are unfortunately not curative. Perhaps not surprisingly,
evidence points to persistent AR signaling as one of the key drivers by which resistances to these agents develops. In
this context, activation of the AR signaling program can occur through a number of molecular adaptations, including
alterations leading to persistent canonical AR signaling (e.g., AR amplification/overexpression, elucidations/concentration
of intratumoral androgens), activation of the AR program via feedback pathways (e.g., AKT/mTOR/Pi3K, HER2/Neu), and
activation of the AR program via mutation or substitution (e.g., AR ligand binding domain mutation; AR splice variants;
glucocorticoid receptor signaling). This review will provide an overview of the more clinical relevant (i.e., druggable)
pathways that have been implicated in the emergence of drug resistance in men with CRPC and highlight some of the
ongoing efforts towards developing therapeutics to impair these mechanisms.
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Background
Androgen deprivation therapy (ADT) has remained
the backbone of treatment for advanced prostate cancer
since the remarkable palliative effects of surgical castra-
tion were first described by Huggins and Hodges back in
the 1940s [1]. While ADT is effective at controlling meta-
static prostate cancer, for the vast majority of patients,
these benefits are short lived, and most will progress to
the lethal phenotype of the disease, so called castration-
resistant prostate cancer (CRPC).
CRPC is defined as progressive prostate cancer in the
face of castrate serum testosterone levels (≤50 ng/dL)
[2, 3]. Older literature has described this disease state
as “hormone refractory”; however, the term “castration-
resistant” has been adopted largely due to the increas-
ing recognition that androgen receptor (AR) signaling
still plays a vital role in driving prostate cancer growth
and remains a viable target in this disease space [4]. In-
deed, the development of newer drugs that function to
inhibit ligand-AR interaction (e.g., abiraterone (an inhibi-
tor of extragonadal androgen synthesis) and enzalutamide
(a potent irreversible AR antagonist)) have provided proof
of principle that the AR remains an important driver of
CRPC growth [5–8].
Perhaps not surprising, more complete AR signaling
inhibition with drugs like abiraterone and enzaluta-
mide has not proven curative, with resistance typically
emerging within a year of drug initiation [5–8]. Our
understanding of resistance mechanisms operating to
drive continued CRPC growth after receipt of either
abiraterone or enzalutamide has clarified that persist-
ent AR signaling is still one of the major drivers.
Persistent activation of the AR signaling program oc-
curs both not only through molecular adaptations of the
AR itself but also through a number of accessory onco-
genic pathways promoting persistent AR activation, ul-
timately leading to progressive prostate cancer. Broadly,
these mechanisms include alterations leading to persist-
ent canonical AR signaling (e.g., AR amplification/over-
expression, elucidations/concentration of intratumoral
androgens), activation of the AR program via feedback
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pathways (e.g., AKT/mTOR/Pi3K, HER2/Neu), and
activation of the AR program via mutation or sub-
stitution (e.g., AR ligand binding domain mutation,
AR splice variants, glucocorticoid receptor signaling)
[9–25].
Detailed reviews have been written on any one of
these pathways, and our goal is not to catalog the
numerous molecular adaptations that can precede the
emergence of CRPC drug resistance. Rather, we seek
to provide an overview of the more clinical relevant
(i.e., druggable) pathways that have been implicated
in the emergence of drug resistance and to highlight
some of the ongoing efforts towards developing ther-
apeutics to impair these mechanisms. This review
will therefore focus on the evidence for several key
mechanisms implicated in promoting sustained AR
signaling, with an emphasis on those that may be
targetable in the near term.
Review
Androgen receptor function and structure
The AR is a nuclear transcription factor encoded on
the X chromosome at position Xq11-Xq12 [26, 27]. It
contains eight exons and is composed of four domains:
the N-terminal domain (i.e., transcriptional activation
domain) (exon 1), DNA-binding domain (exons 2 and 3),
a hinge region (exons 3 and 4), and the ligand-
binding domain (i.e., C-terminal) (exons 4–8) (Fig. 1).
An overly simplistic model of canonical AR signaling
involves: (1) androgen binding the AR ligand binding
domain, (2) dissociation of chaperone proteins (i.e.,
heat shock proteins), (3) AR nuclear transport and
dimerization (likely through microtubule interaction
with the hinge region), (4) binding of dimerized AR
to androgen response elements (ARE) located within
the promoters of AR target genes, (5) recruitment of
AR co-activators, and (6) transcription of AR target
genes. A number of additional events, such as AR phos-
phorylation and interaction with other co-regulators and
transcription factors likely also play a role in modulating
transcription of AR target genes [28].
The AR represents perhaps the first described
lineage-specific oncogene, with prostate cancer demon-
strating a persistent addiction to AR- ignaling even in
its late stages—a reflection of its emergence from nor-
mal prostatic epithelium [29, 30]. The survival of a
given prostate cancer cell is tightly linked to persistent
AR signaling, and as such, these malignant cells will
undergo a number of adaptive changes to ensure per-
sistent AR signaling. Reflective of the reliance of pros-
tate cancer on the expression of AR target genes is the
observation that over 70 % of CRPC cases harbor AR
pathway aberrations, with AR transcriptional activity
persisting in the majority of cases of CRPC [31].
Persistent canonical AR pathway activation
The observation that AR-regulated genes (e.g., PSA) re-
main expressed in a castration-resistant state renewed
interest in targeting the AR in men that had progressed
on LHRH analogue therapy. Ultimately, this work led
to the development of drugs that more effectively in-
hibit the ligand-AR interaction. Abiraterone, a CYP-17 in-
hibitor capable of inhibiting extragonadal testosterone
synthesis (i.e., adrenal and intratumoral) was approved
on the basis that it significantly prolongs survival in
both the pre- and postdocetaxel spaces [6, 7, 32].
Approval for enzalutamide, a potent AR antagonist,
was granted on the basis of a survival advantage in
similar patient populations [5, 8]. The clinical efficacy
of abiraterone and enzalutamide has provided proof
of principal that canonical AR signaling is an import-
ant driver of CRPC growth that can be targeted for
clinical gains.
Interestingly, a correlation between increased full-
length AR (AR-FL) expression and AR copy number
gains with the emergence of resistance to second
generation AR-directed agents has been documented
[9, 11, 33, 34]. This implies that persistent canonical
AR signaling is likely engaged even in the presence
of drugs that should otherwise be able to inhibit AR-
FL from interacting with its ligand (i.e., androgens).
This could be a result of pharmacokinetic issues whereby
drugs are unable to reach sufficient concentrations
within the tumor microenvironment or that intratu-
moral steroidogenesis is able to overcome the inhibi-
tory effects of these agents [35, 36]. A more definitive
explanation for this effect is needed and continues to
be an area of active research.
AR overexpression and copy number alterations
One of the more commonly observed events as pros-
tate cancer progresses from a hormone-sensitive to
castration-resistant state is the adaptive upregulation
of the AR, a finding supported by preclinical as well
as clinical studies [13, 20]. Chen and colleagues dem-
onstrated that a number of prostate cancer cell lines
will adaptively increase their AR expression as they
are passaged in castrate mice over time, and that this
overexpression of AR is sufficient to induce resistance
to the effects of surgical castration as well as treat-
ment with the first-generation anti-androgen bicaluta-
mide [13]. AR overexpression as a driver of resistance
is also supported by data from rapid autopsy pro-
grams showing that AR expression is increased in pa-
tients that have died from CRPC [37, 38]. These
findings provided a strong rationale for developing
drugs like abiraterone and enzalutamide to target per-
sistent AR signaling in men with CRPC.
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In addition, an adaptive increase in AR expression
and AR copy number gain has also been observed in
circulating tumor cells (CTCs) as well as cell-free circu-
lating tumor DNA (ctDNA) from patients with CRPC
receiving next-generation AR-directed therapies (i.e.,
abiraterone and enzalutamide)—implicating this as
mechanism by which cell growth can escape the inhibi-
tory effects of these drugs [9, 11, 33, 34]. Perhaps more
indicative of the importance AR overexpression plays in
promoting CRPC growth comes from the results of a
recently published, large metastatic biopsy program en-
rolling men with CRPC [31]. In that paper, 150 men
with metastatic CRPC underwent biopsy and had suffi-
cient tumor material to undergo integrative genomics
analysis (i.e., whole exome and transcriptome sequen-
cing). That study revealed that the most frequently ob-
served genetic alteration was AR copy number gain,
occurring in 45 % of cases.
Maintenance of intratumoral androgens
In addition to overexpressing AR, there is evidence that
the maintenance of androgens within the tumor micro-
environment may also be an important means by which
canonical AR signaling drives castrate-resistant growth.
In men with hormone-sensitive, localized prostate can-
cer, it has been found that intraprostatic androgens will
fall by ~75 % following initiation of an LHRH analogue
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Fig. 1 Androgen Receptor Structure. a. The AR gene is located on the X chromosome at position Xq11-Xq12. It is composed of eight exons,
which encode for four regions: N-terminal domain (NTD), DNA binding domain (DBD), the hinge region and the ligand binding domain (LBD).
b. Several cryptic exons (CE) as well as exon 9 are involved in the formation of several AR splice variants (AR-Vs) which lack the AR ligand binding
domain. Four of these AR-Vs have been shown to possess constitutive activity (i.e., AR-V3, AR-V4, AR-V7, and AR-V12)
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expression of AR-activated genes such as PSA [39, 40].
In addition, Montgomery and colleagues have shown
that compared to benign prostatic tissue and primary tu-
mors from eugonadal patients, metastases in men with
CRPC had significantly elevated testosterone levels [19].
Interestingly, increased mRNA expression of several ste-
roidogenic enzymes (i.e., 3βHSD, CYP17A1, AKR1C3,
and SRD5A2) accompanied the increased testosterone
concentrations found within metastatic CRPC foci—pro-
viding a mechanistic explanation for why increased an-
drogens levels are found within the metastatic tumor
microenvironment (Fig. 2).
In support of the putative role steroidogenic en-
zymes play in sustaining intratumoral androgens and
subsequent AR activation, cell culture and xenografts
models of CRPC have demonstrated that AKR1C3-
mediated steroidogenesis can lead to the emergence
of resistance to next-generation AR-directed therapies
[41, 42]. Further evidence for the importance that
intratumoral androgen biosynthesis plays in promot-
ing CRPC resistance is provided through experiments
exploring the effects of impairing the activity of key
steroidogenic enzymes. For instance, inhibiting AKR1C3,
an enzyme involved in converting DHEA-S into the po-
tent AR ligands testosterone and dihydrotestosterone
(DHT), has been shown to inhibit prostate cancer cell
growth in cell culture and xenograft models [43, 44]. In
addition, a synergistic anti-tumor effect when indo-
methacin (an AKR1C3 inhibitor) is combined with
either abiraterone or enzalutamide has been reported in
otherwise resistant prostate cancer cell lines [41, 42].
Clinical trials to test the effects of inhibiting AKR1C3
are currently being developed.
The steroidogenic enzyme 3βHSD (encoded by either
HSD3B1 or HSD3B2) is able to catalyze the conversion
of androstenediol to testosterone and also catalyzes the
initial rate-limiting step in converting DHEA to DHT
[45]. As noted above, 3βHSD mRNA levels are higher in
metastases from men with CRPC and correlate with in-
creased intratumoral androgen levels [19]. A gain-of-
function mutation in 3βHSD has also been described
that results in increased DHT production and may be
selected for following chronic castration (i.e., in a
castration-resistant state) [12]. This mutation may also
represent a mechanism by which abiraterone resistance
occurs, as increased 3βHSD activity can result in persist-
ent adrenal steroidogenesis in spite of CYP17 inhibition.
These observations have implicated 3βHSD as a means
by which ligand is able to persist in spite of ADT, raising
the specter that 3βHSD activity may be one of the mech-
anisms leading to castration resistance and indicating
that 3βHSD may be a viable drug target [16].
Of note, abiraterone does function as a weak 3βHSD
inhibitor, and it has been proposed that increased abira-
terone exposure may result in more complete 3βHSD
inhibition [8]. Dose-escalated abiraterone may therefore
have the resultant effect of decreasing the metabolic




































Fig. 2 Steroidogenesis pathway. Enzymes shown to be upregulated in a castration-resistant state are highlighted red. M mineralocorticoid biosynthesis
pathway, G glucocorticoid biosynthesis pathway, A androgen biosynthesis pathway
Schweizer and Yu Journal of Hematology & Oncology  (2015) 8:128 Page 4 of 14
standard dose abiraterone. A clinical trial testing if
dose-escalated abiraterone can further suppress intratu-
moral androgen levels (presumably through impairing
3βHSD activity) is currently underway (clinicaltrials.-
gov: NCT01503229). Interestingly, 3βHSD has also
been shown to catalyze the conversion of abiraterone to
Δ4-abiraterone (D4A), a more potent compound able to
inhibit several steroidogenic enzymes and antagonize
the AR to a degree comparable to enzalutamide [17].
Whether a resistant phenotype emerges following treat-
ment with abiraterone may be in part due to the degree
to which 3βHSD is able to promote DHT vs. D4A pro-
duction. More work to understand the relative contri-
bution that DHT and D4A synthesis plays in promoting
abiraterone response/resistance is needed.
Enhanced androgen and hormone substrate uptake
into the tumor microenvironment may be another ex-
planation accounting for the higher concentration of
androgens found within metastatic foci. Androgen up-
take is mediated by the OATP (organic anion trans-
porting polypeptide) transporter and polymorphisms
in the SLCO family of genes encoding the OATP
transporters have been found to associate with out-
comes [22, 23, 46–49]. For instance, SNP alleles asso-
ciated with enhanced androgen transport or increased
SLCO expression have been correlated with increased
prostate cancer-specific mortality and higher rates of
disease progression [22, 23, 46, 48]. Preclinical studies
have shown that statins are able to competitively bind
SLCO2B1 and prevent uptake of the testosterone precur-
sor DHEAS [23, 50]. Retrospective data has also shown a
correlation between statin use and prolonged time to pro-
gression [50]. Whether this correlation is due to prevent-
ing androgen uptake by the OATP transporter SLCO2B1
or due to decreasing cholesterol—an essential substrate
for all steroid hormones—remains to be seen [51].
AR mutations, variants, and alternate hormone activation
In addition to activating the AR transcriptional pro-
gram via canonical full-length AR signaling, variants of
the AR that occur through alternative splicing or muta-
tions in the ligand binding (i.e., C terminal) domain of
the AR are also able to keep AR signaling engaged in a
castration-resistant state [9, 11, 20, 52–56]. In addition,
other nuclear hormone receptors, such as the gluco-
corticoid receptor (GR), are able to activate a seemingly
similar transcriptional program to the AR and may be a
mechanism by which prostate cancer cells develop re-
sistance to drugs that block AR signaling by disrupting
the AR ligand interaction [57–60].
AR point mutations
A number of point mutations within the ligand-
binding domain of the AR have been described that
result in resistance to first-generation anti-androgens
(e.g., flutamide, nilutamide, and bicalutamide) [61, 62].
Some of these mutations result in increased AR activity
upon exposure to these agents, likely explaining why some
men experience an anti-androgen withdraw effect follow-
ing their cessation [63]. Similarly, the AR mutation F877L
has been found to associate with resistance to the second-
generation AR antagonists enzalutamide and ARN-509,
resulting in AR activation upon exposure to these agents
[34, 64–66]. More recently, preclinical models have dem-
onstrated that the AR antagonist ODM-201 is able to in-
hibit F877L prostate cancer mutant cell growth [67].
Recent phase 1/2 testing has demonstrated that ODM-
201 is well tolerated and is active in men with CRPC [68].
This study did not, however, assess for the presence of the
F877L mutation, and ODM-201’s activity in this subset of
patients remains undefined.
AR splice variant
Over the last few years, it has become increasingly well
recognized that in addition to point mutations, alterna-
tive splicing events that lead to constitutively active AR
variants (AR-Vs) are another clinically relevant means by
which prostate cancer is able to progress in spite of
agents that effectively disrupt the AR-ligand interaction
(Fig. 1) [9, 20, 25, 31, 53–55, 69]. The AR-Vs, the most
commonly occurring AR-V being AR-V7, retain the ability
to activate their transcriptional program in spite of lacking
the AR ligand-binding domain [70]. A recent prospective
biomarker trial reported by Antonarakis et al. found an as-
sociation between the emergence of AR-V7 mRNA tran-
scripts, as measured from CTC, and resistance to
abiraterone and enzalutamide [9]. This data provides an
elegant biologic rationale for why drugs that interfere with
the AR-ligand interaction may not be effective in patients
harboring certain AR-Vs at significant levels; however, it
should be noted that increased AR-FL expression always
accompanied the emergence of AR-V7 transcripts and
was also found to associate with drug resistance (albeit
not as strongly as the presence of AR-V7) [20, 52–56].
Interestingly, AR-V7 does not appear to be predictive
for lack of response to docetaxel—providing a rationale
for precision oncology trials stratifying patients be-
tween AR-directed therapies and chemotherapies on
the basis of AR-V status [71].
Recently, Steinestel et al. reported their experience
using a method similar to the one employed by Anto-
narakis and colleagues for detecting AR-V7 transcripts
[72]. They also found that the presence of AR-V7
transcripts associated with a lack of PSA response to
abiraterone or enzalutamide; however, it should be
noted that one out of five AR-V7-positive patients in
this trial had a PSA response (i.e., ≥50 % decline in
PSA from baseline) to abiraterone, which is in conflict
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with the results reported by Antonarakis et al. Needless to
say, further studies to validate the utility of detectable AR-
V7 transcripts as a predictive and/or prognostic bio-
marker, ideally in the context of a randomized therapeutic
trial, are needed. In addition, mechanistic studies are need
in order to determine if AR-Vs are drivers of resistance or
merely indicative of a larger resistance program being at
play.
The N-terminal domain of the AR is critical for AR
transactivation and subsequent activations of its tran-
scriptional program [73]. As noted above, deletion of
the C-terminal (i.e., ligand-binding domain) may result
in constitutive AR activity, and as such, there are a
number of ongoing efforts to develop drugs capable of
inhibiting the N-terminal domain or its co-activators/
epigenetic regulators, as a means to overcome AR-V-
mediated drug resistance [10, 18, 74]. In addition to directly
targeting the N-terminal domain, drugs intended to sup-
press AR-V expression are also being developed [75–78].
Due to the fact that the AR N-terminal is inherently
unstructured, developing drugs that block AR-signaling
through impairing N-terminal domain activity is not
trivial [79]. Epi-001 and its analogues (e.g., Epi-506) are
small molecule antagonists designed to target the AR
N-terminal domain. They reportedly covalently bind
to the N-terminal domain, thus inhibiting the protein-
protein interactions required for AR-mediated tran-
scription [80]. Importantly, these N-terminal domain
antagonists have been shown to retain activity in pros-
tate cancer cell lines expressing AR-Vs. Of note, Epi-001
may have a broader mechanism of action than first de-
scribed [81]. It has been shown to have general thiol alkyl-
ating activity, resulting in multi-level effects on prostate
cancer cells. In addition to covalently binding to the AR
N-terminal domain, Epi-001 has been shown to inhibit
transcription of the AR gene and to modulate PPARγ ac-
tivity. Likely as a result of these diverse mechanisms of ac-
tion, Epi-001 has also been shown to inhibit the growth of
AR-null prostate cancer cell lines. A phase I/II trial testing
Epi-506, a pro-drug of Epi-001, is planned to open in the
near future [74].
The AR transcriptional machinery is immensely com-
plex and involves not only AR binding to the enhancer
elements of target genes but also the assembly of RNA
polymerase II with a number of co-activator proteins
[31, 82–84]. Much work has gone into understanding
the key regulators of AR-mediated transcription, in an
effort to identify novel therapeutic targets. Genetic
knockdown of HDAC1 or HDAC3 or treatment with an
HDAC inhibitor has been shown to prevent the assem-
bly of the AR-transcriptional complex and prevent ex-
pression of AR-mediated genes [84]. Unfortunately, a
small phase II study testing the HDAC inhibitor romi-
depsin failed to demonstrate sufficient activity in
patients with CRPC [85]. Another strategy by which AR
signaling could be disrupted involves inhibiting one or
more AR co-activators. Bromodomain 4 (BRD4) and
mixed-lineage leukemia (MLL) likely function to regu-
late AR activity and have both been shown to physically
interact with the AR N-terminal domain [10, 18]. Im-
portantly, inhibiting BRD4 or MLL results in an anti-
tumor effect in AR signaling-competent models of CRPC.
It should be noted, however, that epigenetic regulators of
AR transcription are unlikely to be specific to the AR, and
their inhibition may result in altering the transcriptional
program across an array of bystander genes. Prostate
cancer-specific studies testing MLL and bromodomain in-
hibitors have not begun yet, but seem likely to occur in
the future based on this preclinical data.
Multiple drugs have also been shown to suppress
AR-V transcripts and/or protein express. The novel
AR-directed therapeutic galeterone has reportedly three
different mechanisms by which can prevent AR signaling:
(i) inhibiting extragonadal androgen synthesis through
CYP17 inhibition (an enzyme critical to adrenal and pos-
sibly intratumoral androgen production), (ii) preventing
AR nuclear translocation, and (iii) by promoting AR-FL,
mutant AR, and AR-V proteosomal degradation [75, 76,
86]. Based on encouraging results from the phase I/II trial,
a phase III study testing galeterone vs. enzalutamide in
men with AR-V7+ CRPC is planned [87].
Similar to galeterone, the anti-helminthic drug niclosa-
mide has been shown to potentially suppress AR-V ex-
pression [77]. Interestingly, it has no effect AR-V7
mRNA transcript levels. Instead, it has been reported to
enhance AR-V7 degradation, resulting in an anti-
neoplastic effect in otherwise enzalutamide-resistant
prostate cancer cell lines. While this effect is modest
when niclosamide is used alone, it has a synergistic ef-
fect when combined with enzalutamide, likely because
niclosamide does not have effect on AR-FL. Niclosa-
mide’s pharmacokinetics may be a barrier to developing
it as a prostate cancer drug, however, as it has been
found to have poor bioavailability (albeit only in one
small study) [88]. As a strategy to overcome this issue of
bioavailability, a phase I trial testing enzalutamide plus
high-dose niclosamide in AR-V7+ men with CRPC is be-
ing pursued (clinicaltrials.gov: NCT02532114). Of note,
because of niclosamide’s specificity for AR-V7, this trial
may shed some light on the question of whether AR-V7
is a driver of or merely a marker for resistance. That is,
if clinical activity is observed with combination treat-
ment and AR-V7 expression is suppressed, that would
speak to AR-V7 functioning as a driver of resistance. On
the other hand, if there is clinical activity and AR-V7 ex-
pression is unaffected, it would seem more plausible that
AR-V7 is a biomarker for a larger resistance program. If
AR-V7 expression is suppressed and no clinical activity
Schweizer and Yu Journal of Hematology & Oncology  (2015) 8:128 Page 6 of 14
is observed, this may offer some evidence to refute AR-
V7 function as a driver of resistance. Clearly, a small
phase I study will not put this issue to rest, but it could
provide valuable insights regarding the biology of AR-V7
nonetheless.
Preclinical models have shown that castrate andro-
gen levels are able to rapidly induce the expression of
AR-V7 and conversely that supplementation with
supraphysiologic androgen concentrations can acutely
suppress their expression [25, 78]. Based on additional
evidence that supraphysiologic androgens are able to
exert a paradoxical anti-tumor effect in models of
CRPC, a pilot study testing pharmacologic doses of
testosterone was launched [78]. This study documented
radiographic and PSA responses in ~50 % of enrolled
men. Interestingly, the authors observed a possible
resensitization effect whereby following treatment with
testosterone, re-challenge with an AR antagonist (i.e.,
enzalutamide or bicalutamide) resulted in a PSA response.
Similarly, men that had previously progressed on the
next-generation AR-directed therapies abiraterone and
enzalutamide demonstrated high response rates upon
treatment with the alternate agents—contrary to reports
of clinical cross-resistance when these agents are used se-
quentially [6, 89–96]. This effect needs to be confirmed in
larger prospective studies, but it remains possible that
suppression of AR-FL and/or AR-Vs may explain why
some patients appear to be more sensitive to drugs that
inhibit AR signaling following testosterone therapy. A
clinical trial specifically testing the ability of pharmaco-
logic dose testosterone to act as re-sensitizing agent is cur-
rently underway (clinicaltrials.gov: NCT02090114).
Alternate nuclear hormone receptor mediated AR activation
The GR is another nuclear hormone transcription factor
and has been shown to potentially drive castration-
resistant cell growth through activating a similar tran-
scriptional program to the AR [57–59]. A recently
reported neoadjuvant trial testing abiraterone plus LHRH
analogue vs. abiraterone, enzalutamide, and LHRH
analogue for 6 months pre-prostatectomy in men with
high-risk localized prostate cancer supports a role for
both AR-V and GR signaling in conferring resistance
to these potent combinatorial therapies [60]. The authors
found that the loss of AR ligand binding domain, as
measured by immunohistochemistry for the AR-C ter-
minus,and increased GR expression were significantly
correlated with the higher tumor epithelial volume.
Somewhat disappointingly, a small study testing the
GR antagonist mifepristone did not demonstrate evi-
dence of clinical efficacy in CRPC patients; however, the
authors noted an increase in testosterone and DHT
levels after 29 days of therapy—presumably due to feed-
back mechanism leading to increased ACTH production
and in turn higher adrenal androgen biosynthesis [97].
Another strategy being explored is whether combining
mifepristone with enzalutamide, to block any residual
androgens from binding AR, is safe and will lead to im-
proved outcomes (clinicaltrials.gov: NCT02012296).
Whether this strategy will be effective remains to be
seen; however, it should be noted that completely inhi-
biting GR signaling is not compatible with life, and
therapeutic strategies aimed at completely inhibiting its
function are not likely viable [57].
Alternative pathway AR activation
A number of additional oncogenic signaling pathways
interact with and promote persistent AR transcriptional
activity [98]. Pathways commonly affected include the
PI3K, WNT, JAK/STAT, and growth factor pathways. In
addition, phosphoproteomic analyses have implicated a
number of tyrosine kinase signaling pathways as poten-
tial prostate cancer drivers (e.g., SRC, EGFR, RET, ALK,
and MAPK1/3) [15]. Many of these pathways demonstrate
significant cross talk not only with the AR but also between
each other—making it exceedingly difficult to develop an
effective therapeutic strategy that focuses on impairing only
one of the nodes within these complex signaling networks.
Below is a discussion of some of the more commonly
altered pathways in prostate cancer (Fig. 3).
PI3K pathway
Somatic alterations in the PI3K/Akt/mTOR signaling
pathway occur in nearly 50 % of CRPC cases, and there
is evidence that significant cross talk exists between
this and the AR signaling pathway as well as other
oncogenic pathways (e.g., RAS/RAF/MEK) [31, 99–102].
As evidence of the close relationship between the PI3K
and AR signaling pathways, PTEN-deficient models of
prostate cancer have revealed a reciprocal feedback rela-
tionship between these two pathways whereby suppres-
sion of AR signaling promotes PI3K pathway activation,
and conversely, suppression of PI3K signaling results in
AR activation [102]. Importantly, this model demonstrated
that dual inhibition of both pathways resulted in a pro-
found anti-tumor effect.
Genetic aberrations commonly occurring along the
PI3K pathway include biallelic loss of PTEN; mutations,
amplification, and activating fusions in PIK3CA; activat-
ing mutations in PIK3CB; and activating mutations in
AKT1 [31]. PTEN is the most commonly affected gene
in this pathway and is altered in approximately 40 % of
CRPC cases [103, 104]. It acts as a negative regulator of
PI3K/Akt/mTOR signaling and when inactive or lost
leads to pathway over activation. The PI3K signaling
pathway has diverse array of functions and has been im-
plicated in promoting prostate cancer growth, survival,
proliferation, migration, stem cell-like properties and
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angiogenesis [98, 105–108]. Speaking to this pathways
importance, PTEN loss has been correlated with more
advanced stage and higher Gleason scores [109, 110].
There have been a number of efforts to target the
PI3K/Akt/mTOR pathway, and Pan-PI3K, Akt and
mTOR inhibitors are all currently in clinical testing
[101, 111–117]. To date, most of the prostate cancer-
specific experience targeting this pathway comes from
studies testing allosteric mTOR inhibitors, with these
studies all generally failing to demonstrate sufficient ac-
tivity to warrant further study [111–115]. There are a
number of explanations that may explain this lack of
activity. For one, allosteric mTOR inhibitors only inhibit
mTORC1 activity, and evidence supports mTORC2 as
being an important activator of Akt in prostate cancer
cells [118]. Increased reciprocal signaling through other
oncogenic pathways (e.g., AR and RAS/RAF/MEK)
could also render these agents ineffective. Finally, allo-
steric mTORC1 inhibitors do not inhibit key downstream
effectors such as eIF4E, a rate-limiting initiation factor
that has been implicated in mTOR-mediated translation
of a number of oncogenic genes [106]. Ongoing efforts to
target this pathway more effectively include developing
ATP dual mTORC1/mTORC2 inhibitors, Akt inhibitors,
and pan-PI3K inhibitors [101, 105, 119].
Epidermal growth factor pathways
Signaling through the epidermal growth factor (EGF)
and its family of receptors (i.e., EGFR, HER2/Neu,
erbB3, and erbB4) has also been implicated in the
Fig. 3 Androgen receptor activation pathways. AR transcription can occur either through canonical AR-FL signaling or through cross-talk between
alternative signaling pathways. Ligand-independent AR transcription likely occurs through a number of mechanisms and may involve the formation of
AR homodimers (as is the case with the AR-FL canonical signaling pathway) or heterodimerization between AR-FL, AR-Vs, and AR-mutants. Cross-talk
between signaling pathways likely augment AR transcriptional activity in several ways, including through N-terminal phosphorylation, or by promoting
AR nuclear translocation. Key nodes affected by several pathways are highlighted in red. RTK receptor tyrosine kinases, T testosterone, HSP heat-shock
proteins, IL6-R IL-6 receptor, CoReg co-regulators
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growth and progression of prostate cancer [120]. For in-
stance, HER2 has been shown to be inducible in castrate
conditions and to result in elevated AR target genes such
as PSA [121–123]. These pathways’ effects are likely in
large part mediated through MAPK activation, which
can lead to phosphorylation of the AR N-terminal and
subsequent ligand-independent transcription of AR tar-
get genes [24].
Based on the aforementioned observations, a handful
of trials exploring the utility of targeting HER2 and/or
EGFR signaling have been completed [124]. A phase II
trial testing afatinib, a tyrosine kinase inhibitor (TKI)
targeting EGFR and HER2, alone and in combination
with nintedanib, a multi-targeted anti-angiogenic TKI, in
men with CRPC was recently reported [125]. In that
study, afatinib did not demonstrate any clear anti-tumor
activity, with all 20 patients on the afatinib monotherapy
arm progressing after 12 weeks of therapy. Lapatinib, an-
other dual EGFR/HER-2 TKI, has also been tested in
prostate cancer population [126–128]. In a single-arm
phase II study targeting men with biochemically recur-
rent disease (i.e., non-metastatic patients with an ele-
vated PSA), the primary endpoint of PSA50 response
(i.e., ≥50 % decline in PSA from baseline) was not ob-
served in any patients; however, it did appear to favor-
ably augment PSA kinetics, resulting in a decreased PSA
slope [126]. Another study in ADT-naïve patients (meta-
static [5] and non-metastatic [N = 18]) also documented
no PSA50 responses (the primary endpoint). Finally, in a
phase II trial enrolling men with CRPC (both metastatic
[N = 14] and non-metastatic [N = 7]), lapatinib was also
shown to have minimal single agent activity, with only
1/21 patients achieving a PSA50 response (the primary
endpoint) [127]. Similarly disappointing results were ob-
served in studies testing the monoclonal anti-HER2 anti-
bodies trastuzumab and pertuzumab in patients with
CRPC [129, 130]. In total, these trials enrolled 86 patients,
with none of them demonstrated a PSA50 response.
Insulin-like growth factor pathway
Similar to EGFs, the insulin-like growth factors (IGFs)
have far-reaching biologic effects, promoting the growth,
development, and survival of cells [131]. IGF signaling
as it pertains to prostate cancer growth and progression
is likely mediated through type I IGF receptor (IGF-IR)
[132]. IGF-IR signaling demonstrates significant cross
talk with the AR, modulating the AR transcriptional pro-
file, AR nuclear translocation, and AR phosphorylation
profile [132–134]. IGF-I levels have also been linked to a
greater risk of prostate cancer progression [135–138].
Based on these observations, a randomized phase II
study in men with hormone-sensitive metastatic prostate
cancer comparing androgen deprivation therapy with or
without cixutumumab, a monoclonal antibody targeting
IGF-IR, was launched [139]. Ultimately, there was no
significant difference in the rate of undetectable PSA at
28 weeks (the primary endpoint) with the addition of
cixutumumab. Cixutumumab has also been studied in
combination with mitoxantrone in men with CRPC
and was also found to have insufficient activity to
warrant further development [140]. Studies evaluating
cixutumumab as part of a targeted combination strat-
egy have yet to be reported (clinicaltrials.gov: NCT01
026623, NCT00683475).
JAK/STAT pathway
Cytokines, particularly IL-6, have also been implicated
in the maintenance of AR signaling—likely through
enhanced JAK/STAT signaling. IL-6 has also been shown
to associate with advanced stage prostate cancer and sur-
vival [141–144]. STAT3, one of the downstream effectors
of IL-6, can lead to AR-STAT3 complex formation and
subsequent AR activation [145]. Of note, EGFR signaling
is also able to promote AR-STAT3 complex formation,
and STAT3 has been shown to increase EGFR-mediated
AR transcriptional activation—likely indicating that a
complex signaling network exists between AR signaling
and STAT3, IL-6, and EGFR [146].
Agents targeting this pathway include siltuximab, a
monoclonal antibody targeting IL-6. In a phase I pre-
surgical neoadjuvant study testing siltuximab as a mono-
therapy, it was shown to be well tolerated, associates
with increased Ki-67 expression (a marker of apoptosis),
and results in downregulation of genes downstream of
IL-6 [147]. This agent was also tested in a phase I study
combining it with docetaxel at the standard dose of
75 mg/m2 IV every 21 days [148–150]. The combination
was well tolerated, and no PK interaction was noted.
Not surprisingly, since it was given in combination with
docetaxel, a PSA response rate of 62 % was observed. In
contrast, a phase II study comparing siltuximab plus
mitoxantrone vs. mitoxantrone alone was prematurely
terminated due to concern for lack of efficacy at interim
analysis [151].
WNT pathway
Wnt signaling plays an important role in early embry-
onic development as well as in promoting the growth
and progression of several malignancies [131, 152].
Canonical Wnt signaling leads to the accumulation of
β-catenin within the nucleus and leads to target gene
transcription. Cross talk between the canonical Wnt
and AR signaling pathways occurs through β-catenin,
which can augment AR transcriptional activity [153–156].
Non-canonical Wnt signaling may also play a role in pro-
moting prostate cancer cell survival [157]. A recent CTC
transcriptome analysis has demonstrated that non-
canonical Wnt signaling associates with enzalutamide
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drug resistance, and preclinical models suggest that
WNT5A, a ligand of the non-canonical Wnt pathway,
may abrogate the anti-tumor effects of AR inhibition.
Small molecule inhibitors of Wnt/β-catenin have
been developed and shown to inhibit proliferation in
prostate cancer cells [158]. Clinical trials evaluating
specific Wnt signaling inhibitors are currently under-
way (clinicaltrials.gov: NCT01608867), but have yet to
be reported. In addition, there is evidence that the
COX-2 inhibitor celecoxib is able to inhibit Wnt sig-
naling, and a clinical trial testing celecoxib vs. placebo
has been reported [158, 159]. This trial was termi-
nated early due to concerns over the cardiovascular
morbidity associated with celecoxib. The celecoxib arm
demonstrated only modest improvements in PSA dynam-
ics and ultimately further development of COX-2 inhibi-
tors as repurposed prostate cancer drugs seems unlikely.
Conclusions
Even in its late stages, AR signaling remains an import-
ant driver of prostate cancer progression, with most of
the adaptive changes that occur within a prostate can-
cer cell stemming from a persistent addiction to the
AR. As our understanding of the alterations that occur
(e.g., AR mutations, AR alternative splicing events, AR
overexpression/copy number gains, AR substitutions,
ligand persistence, and feedback pathways) in response
to the evolutionary pressure exerted through chronic
AR signaling inhibition, we will hopefully begin to see
the emergence of therapeutic regimens that are able to
impair key resistance mechanisms. Ideally, this will allow
us to offer our patients a personalized regimen based on
their cancer’s molecular profile and the specific resistance
mechanisms operative within them.
The incredible amount of molecular redundancy by
which a malignant prostate cell is able to keep AR sig-
naling engaged remains a critical barrier to the wide de-
ployment of targeted, precision oncology. Clinical trials
targeting these accessory pathways have, to date, been
mostly unsuccessful. A key issue not addressed in past
trials is the issue of cross talk between pathways other
than the AR. It is likely that combination therapeutic
trials are necessary if these other pathways are to be ef-
fectively targeted in the clinic.
Our understanding for how prostate cancers are able
to progress in spite of drugs that should effectively pre-
vent canonical AR signaling (i.e., abiraterone and enza-
lutamide) is growing exponentially. Armed with this
improved understanding, the next challenge will be to
take this knowledge and translate it into the next gener-
ation of targeted therapies—allowing us to extend the
health and well-being of men suffering with the most
advanced forms of CRPC.
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